Literature DB >> 33022538

The association of prefrontal cortex response during a natural reward cue-reactivity paradigm, anhedonia, and demoralization in persons maintained on methadone.

Andrew S Huhn1, Robert K Brooner2, Mary M Sweeney2, Denis Antoine2, Alexis S Hammond2, Hasan Ayaz3, Kelly E Dunn2.   

Abstract

Persons with opioid use disorder (OUD) often experience anhedonia and demoralization, yet there is relatively little research on the pathophysiology of anhedonia and demoralization in OUD treatment and recovery. In the current study, persons maintained on methadone (N = 29) underwent a natural reward-cue paradigm during functional near-infrared spectroscopy (fNIRS) imaging. Natural reward cues included highly palatable food, positive social interactions (e.g., a happy family at the dinner table), and emotional intimacy (e.g. couples embracing or kissing, but no erotic images). Participants also self-reported symptoms of anhedonia on the Snaith-Hamilton Pleasure Scale (SHPS) and demoralization on the Demoralization Scale II (DS-II). Participants who reported clinically-significant anhedonia on the SHPS displayed decreased neural activity in the right prefrontal cortex (PFC) in response to natural reward cues (F(1,25) = 3.612, p = 0.027, ηp2 = 0.302). In linear regression models of positive social cues, decreased neural activity in the right VMPFC was associated with increased SHPS total score (F(1,27) = 7.131, R2 = 0.209, p = .013), and decreased neural activity in an area encompassing the right lateral VMPFC and DLPFC was associated with increased DS-II total score (F(1,27) = 10.641, R2 = 0.283, p = 0.003). This study provides initial evidence that the prefrontal cortex is involved in the pathophysiology of anhedonia and demoralization in persons in recovery from OUD. Anhedonia and demoralization are important treatment outcomes that should be queried along with a constellation of physical and mental health outcomes, to assess areas of needed improvement in methadone maintenance and other OUD treatment modalities.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anhedonia; Demoralization; Depressive symptoms; Medications for opioid use disorder; Methadone; Opioid use disorder; Prefrontal cortex

Mesh:

Substances:

Year:  2020        PMID: 33022538      PMCID: PMC7736228          DOI: 10.1016/j.addbeh.2020.106673

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  53 in total

1.  Sliding-window motion artifact rejection for Functional Near-Infrared Spectroscopy.

Authors:  Hasan Ayaz; Meltem Izzetoglu; Patricia A Shewokis; Banu Onaral
Journal:  Annu Int Conf IEEE Eng Med Biol Soc       Date:  2010

2.  Anhedonia and substance-related symptoms in detoxified substance-dependent subjects: a correlation study.

Authors:  L Janiri; G Martinotti; T Dario; D Reina; F Paparello; G Pozzi; G Addolorato; M Di Giannantonio; S De Risio
Journal:  Neuropsychobiology       Date:  2005-06-03       Impact factor: 2.328

Review 3.  Medication Treatment of Opioid Use Disorder.

Authors:  James Bell; John Strang
Journal:  Biol Psychiatry       Date:  2019-07-02       Impact factor: 13.382

4.  Ecological momentary assessment of affect and craving in patients in treatment for prescription opioid dependence.

Authors:  Andrew S Huhn; Jonathan Harris; H Harrington Cleveland; David M Lydon; Dean Stankoski; Michael J Cleveland; Erin Deneke; Scott C Bunce
Journal:  Brain Res Bull       Date:  2016-02-11       Impact factor: 4.077

5.  Refinement and revalidation of the demoralization scale: The DS-II-internal validity.

Authors:  Sophie Robinson; David W Kissane; Joanne Brooker; Natasha Michael; Jane Fischer; Michael Franco; Courtney Hempton; Merlina Sulistio; Julie F Pallant; David M Clarke; Susan Burney
Journal:  Cancer       Date:  2016-05-12       Impact factor: 6.860

Review 6.  Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.

Authors:  Kelly E Dunn; Andrew S Huhn; Cecilia L Bergeria; Cassandra D Gipson; Elise M Weerts
Journal:  J Pharmacol Exp Ther       Date:  2019-08-07       Impact factor: 4.030

7.  Integration of Buprenorphine Treatment with Primary Care: Comparative Effectiveness on Retention, Utilization, and Cost.

Authors:  Yea-Jen Hsu; Jill A Marsteller; Sarah G Kachur; Michael I Fingerhood
Journal:  Popul Health Manag       Date:  2018-12-13       Impact factor: 2.459

8.  Possible evidence for re-regulation of HPA axis and brain reward systems over time in treatment in prescription opioid-dependent patients.

Authors:  Scott C Bunce; Jonathan D Harris; Edward O Bixler; Megan Taylor; Emilie Muelly; Erin Deneke; Kenneth W Thompson; Roger E Meyer
Journal:  J Addict Med       Date:  2015 Jan-Feb       Impact factor: 3.702

9.  Anhedonia as a key clinical feature in the maintenance and treatment of opioid use disorder.

Authors:  Brian D Kiluk; Sarah W Yip; Elise E DeVito; Kathleen M Carroll; Mehmet Sofuoglu
Journal:  Clin Psychol Sci       Date:  2019-09-23

10.  Using MazeSuite and functional near infrared spectroscopy to study learning in spatial navigation.

Authors:  Hasan Ayaz; Patricia A Shewokis; Adrian Curtin; Meltem Izzetoglu; Kurtulus Izzetoglu; Banu Onaral
Journal:  J Vis Exp       Date:  2011-10-08       Impact factor: 1.355

View more
  5 in total

1.  Mindful Positive Emotion Regulation as a Treatment for Addiction: From Hedonic Pleasure to Self-Transcendent Meaning.

Authors:  Eric L Garland
Journal:  Curr Opin Behav Sci       Date:  2021-04-24

2.  Neural correlates of cognitive control in women with a history of sexual violence suggest altered prefrontal cortical activity during cognitive processing.

Authors:  Laura Sinko; Paul Regier; Adrian Curtin; Hasan Ayaz; Anna Rose Childress; Anne M Teitelman
Journal:  Womens Health (Lond)       Date:  2022 Jan-Dec

3.  Commentary on Zolopa et al.: Trauma as an impediment to successful aging and a precipitant of opioid and stimulant use among older adults.

Authors:  Andrew S Huhn; Jennifer D Ellis
Journal:  Addiction       Date:  2022-03-29       Impact factor: 7.256

4.  Sleep disturbance as a therapeutic target to improve opioid use disorder treatment.

Authors:  Andrew S Huhn; Patrick H Finan
Journal:  Exp Clin Psychopharmacol       Date:  2021-06-10       Impact factor: 3.157

5.  Frontal Lobe Functions, Demoralization, Depression and Craving as Prognostic Factors and Positive Outcomes of Patients with Heroin Use Disorder Receiving 6 Months of Methadone Maintenance Treatment.

Authors:  Ting-Gang Chang; Ting-Ting Yen; Wen-Yu Hsu; Shan-Mei Chang
Journal:  Int J Environ Res Public Health       Date:  2022-03-20       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.